Cytokinetics, Inc.’s (CYTK) share price has entered into oversold territory with an RSI value of 28.94. The Zacks Consensus Estimate on Cytokinetics, Inc.’s earnings for the full year period has profit by 0.00 cents over the past two months to $-1.71 per share. Currently, Cytokinetics, Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (CYTK) after its recent drop.
CYTOKINETICS (CYTK): Free Stock Analysis Report
Zacks Investment Research
- Personal Investing Ideas & Strategies